Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
/
Mersana Therapeutics
Create a narrative
Mersana Therapeutics Community
NasdaqGS:MRSN Community
2
Narratives
written by author
0
Comments
on narratives written by author
17
Fair Values set
on narratives written by author
Community Investing Ideas
Mersana Therapeutics
Popular
Undervalued
Overvalued
Mersana Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Precision Medicine And Global Aging Will Open Opportunities
Key Takeaways Emi-Le's broader therapeutic potential, enhanced dosing strategies, and demographic trends position Mersana for outsized growth and margin expansion in breast cancer markets. Strategic collaborations and proprietary ADC platforms diversify revenue, reduce cash burn, and support long-term growth in precision medicine.
View narrative
US$50.00
FV
84.7% undervalued
intrinsic discount
-7.37%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Mersana Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
ADC Trials Will Reshape Personalized Cancer Treatments
Key Takeaways Advancements in targeted oncology therapeutics and strategic partnerships are diversifying income, reducing dilution risk, and strengthening long-term financial stability. Differentiated clinical assets and alignment with personalized medicine trends position the company for accelerated growth, premium pricing, and possible M&A or licensing opportunities.
View narrative
US$28.29
FV
73.0% undervalued
intrinsic discount
-5.77%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
12 days ago
author updated this narrative
Your Valuation for
MRSN
MRSN
Mersana Therapeutics
Your Fair Value
US$
Current Price
US$7.65
87.6% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-215m
80m
2015
2018
2021
2024
2025
2027
2030
Revenue US$79.5m
Earnings US$16.5m
Advanced
Set Fair Value